Psoriatic arthritis improved on risankizumab: does the presence of psoriatic arthritis mean a drug approved for psoriatic arthritis has to be prescribed?

Expert Opin Biol Ther. 2022 Dec;22(12):1439-1441. doi: 10.1080/14712598.2022.2088278. Epub 2022 Jun 13.

Authors

Rohan Singh¹, Alexandria M Brown¹, Warren H Chan¹, Morgan A Farr¹, Sid Venkataraman¹, Steven R Feldman^{1

2

3}

Affiliations

¹ Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
² Department of Pathology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
³ Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.

PMID: 35678210
DOI: 10.1080/14712598.2022.2088278

No abstract available

Keywords: FDA approval; Psoriasis; biologic agent; psoriatic arthritis; risankizumab.

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal / therapeutic use
Arthritis, Psoriatic* / drug therapy
Humans
Psoriasis* / drug therapy

Substances

risankizumab
Antibodies, Monoclonal